Let’s Keep the Door to Biotechnological Eugenics Closed
By Enola Aird,
MomsRising
| 02. 10. 2014
Remember the
three-parent babies I told you about in December? The ones made with genetic material from two different women? Well, the United States might be moving a step closer to their creation.
A Food and Drug Administration (FDA) Advisory Committee will hold a
public meeting on February 25 and 26 regarding clinical trials of mitochondrial transfer procedures (MT). I’ve submitted a written
statement and received FDA permission to present my arguments at the meeting. I’ll be there to oppose the use of such procedures because they would permanently change the genes passed down to future generations.
A quick reminder of what’s at stake. The Advisory Committee will consider whether to allow human clinical trials of “oocyte modification in assisted reproduction for the prevention of the transmission of mitochondrial disease or treatment of infertility.” That’s a long way of referring to a form of genetic modification that would alter an embryo’s genetic structure in such a way that the changes would be passed down to all future generations of the same line.
To accomplish this sci-fi sounding task, scientists would...
Related Articles
By Abby Vesoulis, Mother Jones | 04.18.2026
Two years ago, we devoted an entire issue to the rise of the American oligarchy. Since then, our oligarchic system has become more entrenched and pervasive, revolving around a small crew of tech titans whose quest for wealth and...
By Peter Ward, Slate | 03.30.2026
I’m in a cramped examination room at a clinic in Panama City. The lights are dim, and calming classical music plays from built-in speakers. A nurse has injected a dose of stem cells into Kenneth Scott through an IV in...
By Fyodor D. Urnov and Sadik H. Kassim, Nature | 04.21.2026
In February, the US Food and Drug Administration (FDA) proposed a radical rethink of how scientists, physicians and manufacturers develop personalized genetic therapies. The regulator’s suggested introduction of a ‘plausible mechanism pathway’ should increase incentives for drug companies to develop...
By Carly Mallenbaum, Axios [cites Emily Galpern] | 03.29.2026
More Americans are turning to surrogacy to build their families, as the practice becomes more common and more publicly discussed.
Why it matters: As surrogacy becomes more visible and accessible, ethical, legal and cultural tensions become harder to ignore...